Leadership team

    Will Downie

    Chief Executive Officer

    Appointment

    Will Downie was appointed Chief Executive Officer in November 2019.

    Experience and Expertise

    Will holds a BSc (Hons) in biochemistry from the University of Edinburgh.

    Prior to joining Vectura, Will spent ten years as the senior vice president, global sales and marketing at Catalent Inc. In this role, Will led the commercial effort and had responsibility for global sales, marketing and commercial operations activities. During his tenure, he developed an outstanding track record in helping drive the long-term growth of the company, as well as positioning Catalent as one of the leading brands in the pharmaceutical services space.

    He has a deep understanding of the drug development and advanced drug delivery market, and has amassed significant experience in driving sustained long-term results, as well as building performance-focused organisations and meeting customer needs on a global scale.

    Prior to Catalent, Will held positions as vice president and general manager, global molecular imaging at GE Healthcare, vice president sales EMEA at Amersham Health and director of business development and commercial operations at Quintiles Innovex UK Limited. In his early career, he worked in a range of sales and marketing management positions at both Sanofi and Merck & Co.

    Current external appointments

    Will does not currently hold any other directorships.

    Paul Fry

    Chief Financial Officer

    Appointment to the Board

    Paul Fry was appointed Chief Financial Officer in October 2018.

    Experience and Expertise

    He graduated from Oxford University in 1988 and qualified as an accountant with the Chartered Institute of Management Accountants in 1991.

    Paul joined Vectura from Immunocore, a privately held T-cell receptor biotechnology company, where he was chief financial officer. Before joining Immunocore, he served as director of global finance operations at Vodafone Plc, where he was responsible for key financial controller activities and core processes as well as large transformation programmes. Prior to his role at Vodafone, he spent more than 25 years at GlaxoSmithKline (GSK), where he held a number of senior roles including head of global finance services and CFO for GSK’s Italian pharmaceutical business.

    Current external appointments

    In February 2020 Paul became a non-executive director of AIM-listed Avacta Group plc, a developer of Affimer® biotherapeutics and reagents, and is also Avacta’s audit committee chairman.

    John Murphy

    General Counsel and Company Secretary

    Appointment

    John Murphy joined Skyepharma as general counsel in March 2006 and was appointed as General Counsel and Company Secretary of Vectura in June 2016 following the merger.

    Experience and expertise

    John is a lawyer with extensive experience in legal and company secretarial roles in listed pharmaceutical and biotechnology companies including Medeva PLC, Celltech Group PLC and Pharmagene PLC. He is chairman of the BIA Intellectual Property Advisory Committee and a member of the EuropaBio Intellectual Property Working Group. He holds a BSc in aeronautical engineering from Bristol University and is a qualified solicitor.

    Mark Bridgewater

    Chief Commercial Officer

    Appointment
    Mark Bridgewater joined Vectura in March 2020.

    Experience and expertise

    Mark has more than 25 years experience in medical device and pharmaceutical B2B services. Prior to joining Vectura he was VP business development and account management for Europe and Asia at Flex in the Health Solutions business unit, a global design, engineering and manufacturing organisation. Prior to this, he was VP global business development, advanced delivery technologies at Catalent, and earlier in his career worked as head of global contract manufacturing services at Wockhardt and in various commercial roles at Patheon in Italy.

    Sharon Johnson

    Executive Vice President - Inhaled Product Solutions

    Appointment

    Sharon Johnson joined Vectura in February 2020.

    Experience and Expertise

    Sharon holds a postgraduate diploma in industrial pharmaceutical studies with distinction from Brighton University and a BSc honours degree in applied biology/microbiology from North East Surrey College of Technology. She is a Fellow of the Royal Society of Biology and a registered Qualified Person.

    Sharon has more than 30 years’ experience in the pharmaceutical industry. Prior to joining Vectura she held a number of executive positions, most recently senior vice president, global quality and regulatory affairs, at Catalent, where her role was expanded to include responsibility for product development and the implementation of a project management organisation with strong governance and transparency, ensuring customer expectations of product development excellence were delivered. Earlier in her career she held the position of vice president of quality for GE Healthcare’s medical diagnostic division, and worked in roles of increasing responsibility for Baxter Healthcare and Sanofi Aventis.

    Geraldine Venthoye

    Chief Scientific Officer & Executive Vice President Technology, Science & Innovation

    Appointment

    Dr Geraldine Venthoye joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC, where she had been executive vice president – pharmaceutical development since 2013. She joined Skyepharma as head of the inhalation business unit in September 2003.

    Experience and expertise

    Geraldine is a UK registered pharmacist and holds a doctorate degree in pharmaceutics from the University of London and has spent 30 years in inhaled drug delivery R&D.

    Geraldine previously held senior CMC leadership and scientific roles at Inhale/Nektar Therapeutics, San Carlos, California, US, and Vandsons Research and Norton Healthcare in the UK. She completed her pre-registration clinical training at the Brompton Heart and Lung Hospital in London.

    Antony Fitzpatrick

    Executive Vice President Operations

    Appointment

    Antony Fitzpatrick joined Vectura in July 2017.

    Experience and expertise

    Antony has a first-class BSc in aeronautical engineering from Manchester University and an MSc in numerical computation from the University of Manchester Institute of Science and Technology.

    Antony joined Vectura from Baxter where he had worked since 1999, having been responsible for global supply chain and also manufacturing across EMEA. His Baxter experience includes operating in both a pharma product environment and in product device and pure medical device operations. He sat on the board of GHX, the Global Healthcare Exchange, for four years prior to its sale to private equity. Before working at Baxter he worked in various manufacturing and logistics roles of increasing responsibility for Ingram Micro (IT technology), Exel Logistics, Coopers and Lybrand and Mobil Oil.

    Joanne Hombal

    Executive Vice President – Human Resources

    Appointment

    Joanne Hombal joined Vectura in January 2015.

    Experience and expertise

    Joanne has a BSc in psychology from the University of Birmingham and a postgraduate diploma in human resource management from the University of Glamorgan. She is a Chartered Member of the Institute of Personnel and Development.

    Before joining Vectura, Joanne was vice president HR at Invensys Rail, with responsibility for setting and leading the people strategy for Northern Europe. She has held senior HR roles in the financial services and ICT industries and led a number of organisational development and transformation initiatives.